Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)†.

MLA

Yokomizo, Akira, et al. “Salvage Radiotherapy Versus Hormone Therapy for Prostate-Specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-Label, Phase 3 Trial (JCOG0401)†.” European Urology, vol. 77, no. 6, June 2020, pp. 689–98. EBSCOhost, https://doi.org/10.1016/j.eururo.2019.11.023.

APA

Yokomizo, A., Wakabayashi, M., Satoh, T., Hashine, K., Inoue, T., Fujimoto, K., Egawa, S., Habuchi, T., Kawashima, K., Ishizuka, O., Shinohara, N., Sugimoto, M., Yoshino, Y., Nihei, K., Fukuda, H., Tobisu, K., Kakehi, Y., & Naito, S. (2020). Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)†. European Urology, 77(6), 689–698. https://doi.org/10.1016/j.eururo.2019.11.023

Chicago

Yokomizo, Akira, Masashi Wakabayashi, Takefumi Satoh, Katsuyoshi Hashine, Takahiro Inoue, Kiyohide Fujimoto, Shin Egawa, et al. 2020. “Salvage Radiotherapy Versus Hormone Therapy for Prostate-Specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-Label, Phase 3 Trial (JCOG0401)†.” European Urology 77 (6): 689–98. doi:10.1016/j.eururo.2019.11.023.